Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel - PubMed

Comparative Study

Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel

Maria Laura Immordino et al. J Control Release. 2003.

Abstract

The taxanes, paclitaxel and docetaxel, are anticancer agents used in clinical trials against ovarian carcinoma, breast, lung and head/neck cancer. Paclitaxel, very insoluble in water, is generally formulated using Cremophor EL. Docetaxel, more soluble in water, is formulated using Tween 80 and ethanol. Tween 80, albeit less toxic than Cremophor EL, may be responsible of some toxic effects. To eliminate these vehicles and improve the drug's antitumor efficacy, taxanes have been incorporated in liposomes. We compared formulation, stability, biodistribution and pharmacokinetics of docetaxel in conventional and PEGylated liposomes. Of the several formulations examined, docetaxel-liposomes composed of ePC/PG/CHOL 9:1:2 and ePC/PG/DSPE-PEG2000/CHOL 9:1:2:0.7 were the most effective. Both conventional and PEGylated docetaxel-liposomes were stable at 4 degrees C after 15 days, whereas in the presence of serum at 37 degrees C they were less stable. The IC50 values of docetaxel-liposomes, evaluated on HT-29 and Igrov1 cell lines, remained very high. Pharmacokinetics and biodistribution were evaluated in Balb/c mice after i.v. injection of [14C]docetaxel, formulated in Tween 80 or in 3H-labeled conventional or PEGylated liposomes. The t(1/2)beta, which was low for docetaxel (52.3 min), rose to 260 min for conventional docetaxel-liposomes and to 665 min for PEGylated docetaxel liposomes. Biodistribution studies confirmed the pharmacokinetics.

Similar articles

• Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes.

  Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L. Crosasso P, et al. J Control Release. 2000 Jan 3;63(1-2):19-30. doi: 10.1016/s0168-3659(99)00166-2. J Control Release. 2000. PMID: 10640577

• Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery.

  Zhai G, Wu J, Xiang G, Mao W, Yu B, Li H, Piao L, Lee LJ, Lee RJ. Zhai G, et al. J Nanosci Nanotechnol. 2009 Mar;9(3):2155-61. doi: 10.1166/jnn.2009.450. J Nanosci Nanotechnol. 2009. PMID: 19435095 Free PMC article.

• Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.

  Sharma A, Straubinger RM, Ojima I, Bernacki RJ. Sharma A, et al. J Pharm Sci. 1995 Dec;84(12):1400-4. doi: 10.1002/jps.2600841204. J Pharm Sci. 1995. PMID: 8748320

• Preclinical pharmacokinetics of paclitaxel and docetaxel.

  Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Sparreboom A, et al. Anticancer Drugs. 1998 Jan;9(1):1-17. doi: 10.1097/00001813-199801000-00001. Anticancer Drugs. 1998. PMID: 9491787 Review.

• Preclinical pharmacology of the taxanes: implications of the differences.

  Gligorov J, Lotz JP. Gligorov J, et al. Oncologist. 2004;9 Suppl 2:3-8. doi: 10.1634/theoncologist.9-suppl_2-3. Oncologist. 2004. PMID: 15161985 Review.

Cited by

• Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid.

  Keum CG, Noh YW, Baek JS, Lim JH, Hwang CJ, Na YG, Shin SC, Cho CW. Keum CG, et al. Int J Nanomedicine. 2011;6:2225-34. doi: 10.2147/IJN.S24547. Epub 2011 Oct 7. Int J Nanomedicine. 2011. PMID: 22114486 Free PMC article.

• Ionically fixed polymeric nanoparticles as a novel drug carrier.

  Lee SW, Chang DH, Shim MS, Kim BO, Kim SO, Seo MH. Lee SW, et al. Pharm Res. 2007 Aug;24(8):1508-16. doi: 10.1007/s11095-007-9269-5. Epub 2007 Mar 23. Pharm Res. 2007. PMID: 17380262

• Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.

  Immordino ML, Dosio F, Cattel L. Immordino ML, et al. Int J Nanomedicine. 2006;1(3):297-315. Int J Nanomedicine. 2006. PMID: 17717971 Free PMC article. Review.

• Metalloporphyrin intercalation in liposome membranes: ESR study.

  Man D, Słota R, Broda MA, Mele G, Li J. Man D, et al. J Biol Inorg Chem. 2011 Jan;16(1):173-81. doi: 10.1007/s00775-010-0715-1. Epub 2010 Oct 21. J Biol Inorg Chem. 2011. PMID: 20963616 Free PMC article.

• A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment.

  Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, Chen H, Sun H, Tian Y, Liu K, Li Z, Huang L. Mei L, et al. Nanoscale Res Lett. 2009 Sep 16;4(12):1530-9. doi: 10.1007/s11671-009-9431-6. Nanoscale Res Lett. 2009. PMID: 20652101 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database